Search Results - "Sengeløv, L"

A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy by Fizazi, K., Ulys, A., Sengeløv, L., Moe, M., Ladoire, S., Thiery-Vuillemin, A., Flechon, A., Guida, A., Bellmunt, J., Climent, M.A., Chowdhury, S., Dumez, H., Matouskova, M., Penel, N., Liutkauskiene, S., Stachurski, L., Sternberg, C.N., Baton, F., Germann, N., Daugaard, G.

“…This phase II study was conducted to assess clinical efficacy of tasquinimod maintenance therapy in patients with metastatic castrate-resistant prostate cancer…”
Get full text

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer by Roberts, J.T., von der Maase, H., Sengeløv, L., Conte, P.F., Dogliotti, L., Oliver, T., Moore, M.J., Zimmermann, A., Arning, M.

“…Purpose: To compare long-term survival in patients with locally advanced and metastatic transitional cell carcinoma (TCC) of the urothelium treated with…”
Get full text

ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of invasive bladder cancer by Sengeløv, L

Get full text

Pattern of dissemination and survival following isolated locoregional recurrence of breast cancer : A prospective study with more than 10 years of follow up by KAMBY, C, SENGELØV, L

“…The study evaluated prognostic factors for dissemination and survival in patients with local or regional recurrence of breast cancer. Furthermore, the aim was…”
Get full text

Age-related Differences in Recall of Information and Handling of Chemotherapy-related Side Effects in Cancer Patients: The ReCap Study by Lund, Cecilia Margareta, Mikkelsen, M K, Theile, S, Michelsen, H M, Schultz, M, Sengeløv, L, Nielsen, D L

“…To prevent severe toxicity and hospital admissions, adequate management and recall of information about side effects are crucial and health literacy plays an…”
Get full text

Radiotherapy in bladder cancer by Sengeløv, Lisa, von der Maase, Hans

“…In the present review, we have evaluated the outcome of radiotherapy in patients with bladder cancer. The exact value of radical radiotherapy is difficult to…”
Get full text

Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study by Sengeløv, L, Kamby, C, Lund, B, Engelholm, S A

“…Docetaxel and cisplatin has documented single-agent activity and different toxicity profiles in patients with metastatic urothelial cancer. We performed a…”
Get more information

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer by DROR MICHAELSON, M, OUDARD, Stephane, LAESTADIUS, Fredrik, ULLEN, Anders, BAHL, Amit, CASTELLANO, Daniel, GSCHWEND, Juergen, MAURINA, Tristan, CHOW MANEVAL, Edna, WANG, Shaw-Ling, LECHUGA, Maria Jose, PAOLINI, Jolanda, OU, Yen-Chuan, ISAN CHEN, SENGELØV, Lisa, SAAD, Fred, HOUEDE, Nadine, OSTLER, Peter, STENZL, Arnulf, DAUGAARD, Gedske, JONES, Robert

“…We evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC). Men with…”
Get full text

Survival and Pattern of Failure Following Locoregional Recurrence of Breast Cancer by Kamby, C., Sengeløv, L.

“…This study analyzed prognostic factors at primary diagnosis and at first recurrence for impact on survival after isolated locoregional failure. The aims were:…”
Get full text

p53 nuclear immunoreactivity as a predictor of response and outcome following chemotherapy for metastatic bladder cancer by SENGELØV, L, HORN, T, STEVEN, K

“…p53 nuclear immunoreactivity was determined in primary bladder tumours from 50 patients who developed metastatic bladder cancer. We investigated the…”
Get full text

Metastatic urothelial cancer: evaluation of prognostic factors and change in prognosis during the last twenty years by Sengeløv, L, Kamby, C, von der Maase, H

“…This study was designed to establish prognostic factors for survival of patients with locally advanced or metastatic urothelial cancer. We have furthermore…”
Get more information

Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma by Sengeløv, L, Kamby, C, von der Maase, H

“…The anatomical pattern of recurrence and metastases in patients with urothelial cancer are described, and the relationship between treatment and features of…”
Get more information

213 POSTER Phase II multicenter trial of belinostat (PXD101) in combination with carboplatin and paclitaxel (BelCaP) for patients (pts) with transitional cell carcinoma (TCC) of the bladder by Barriuso, J, Daugaard, G, Frentzas, S, Fuglsang, L, Glasspool, R, Krarup-Hansen, A, Jones, R.J, Lassen, U, Sengeløv, L, De Bono, J.S

Get full text

P069 Low-dose prednisolone in first-line docetaxel for patients with metastatic castration-resistant prostate cancer. Is there a clinical benefit? by Kongsted, P, Svane, I.M, Daugaard, G, Lindberg, H, Sengeløv, L

Get full text

Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract by Sengeløv, L, Kamby, C, Schou, G, von der Maase, H

“…Prognostic factors for patients with disseminated transitional cell carcinoma of the urothelium (TCC) has been examined only in patients selected for studies…”
Get more information

7105 POSTER DISCUSSION Belinostat in Combination With Carboplatin and Paclitaxel (BelCaP) for Treatment of Bladder Cancer – A Pharmacokinetic Study of Exposure to Belinostat and Its Metabolites by Jones, R.J, Tjornelund, J, Erichsen, K.D, Sengelov, L, De Bono, J

Get full text

Dendritic cell vaccination in combination with docetaxel for patients with prostate cancer – a randomized phase II study by Kongsted, P., Ellebæk, E., Borch, T.H., Iversen, T.Z., Andersen, R., Met, Ö, Hansen, M., Sengeløv, L., Svane, I.M.

Get full text

FIRSTANA: Health-related quality of life (HRQL) and post-hoc analyses for the phase III study assessing cabazitaxel (C) vs docetaxel (D) in chemotherapy-naïve patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Oudard, S., Sartor, O., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjelm-Eriksson, M., Jassem, J., Thiery-Vuillemin, A., Caffo, O., Castellano, D., Mainwaring, P.N., Bernard, J., Shen, L., Chadjaa, M., Fizazi, K.

Get full text

683 Androgen deprivation therapy improve disease free survival in patients treated with salvage radiotherapy – A national Danish study by Ervandian, M, Høyer, M, Elleberg, Petersen S, Sengeløv, L, Hansen, S, Holmberg, M, Svejstrup, J, Meidahl, Petersen P, Borre, M

Get full text

Ultrasonically guided insertion of a peritoneo-gastric shunt in patients with malignant ascites by Lorentzen, T, Sengeløv, L, Nolsøe, C P, Khattar, S C, Karstrup, S, von der Maase, H

“…A new method for internal drainage of malignant ascites is presented in 5 patients with symptomatic malignant ascites. US-guided percutaneous gastrostomy and…”
Get more information